MC 4262

Drug Profile

MC 4262

Alternative Names: MC 1/Angiotensin Receptor Blocker; MC 1/ARB; Pyridoxal phosphate/Angiotensin Receptor Blocker

Latest Information Update: 18 Aug 2014

Price : $50

At a glance

  • Originator Medicure
  • Class Antihypertensives; Ischaemic heart disorder therapies; Picolines
  • Mechanism of Action Angiotensin receptor antagonists; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension; Metabolic syndrome

Most Recent Events

  • 18 Aug 2014 Discontinued - Phase-I for Metabolic syndrome in Canada (PO)
  • 18 Aug 2014 Discontinued - Phase-I for Hypertension in Canada (PO)
  • 12 May 2005 Phase-I clinical trials in Metabolic syndrome in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top